Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

PharmaCielo (PCLOF) Stock Price & Analysis

90 Followers

PCLOF Stock Chart & Stats

$0.03$0.00(0.00%)
At close: 4:00 PM EST
$0.03$0.04$0.05Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$0.03 - $0.04
52-Week Range
$0.00 - $0.12
Previous Close
$0.03
Volume
N/A
Average Volume (3M)
6,010
Market Cap
$6.56M
Enterprise Value
$31.59M
Total Cash (Recent Filing)
$77.50K
Total Debt (Recent Filing)
$18.21M
Price to Earnings (P/E)
―
Beta
-1.69
Next Earnings
May 03, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

The strong TTM revenue rebound indicates improving commercial traction and greater product sales across the company’s markets. If maintained, higher volume can provide operating leverage, support reinvestment, and move the business closer to covering its fixed operating costs.

Gross Margin Improvement

Expansion in gross margin suggests better pricing, product mix, and/or cost control in the underlying ingredient business. Sustained improvement would increase the contribution from each sale and create a stronger foundation for eventually converting revenue growth into operating profitability.

B2B Ingredient Model

The B2B model positions PharmaCielo as an ingredient supplier for medical, wellness, and pharmaceutical-related applications rather than relying only on a single finished-product channel. This provides multiple potential end uses for its processed cannabis derivatives.

Bears Say

Negative Equity And Debt

Negative equity and a sizable debt balance indicate a strained capital structure and limited financial flexibility. This can increase refinancing pressure and make future funding more dependent on external capital, while potential dilution may constrain the benefits of any operational recovery.

Negative Cash Generation

The company is consuming cash rather than funding operations internally, and the negative cash-flow profile has persisted across the historical periods provided. Continued cash use raises liquidity and financing dependence, limiting the resources available for growth and operational improvement.

Ongoing Losses

Despite revenue and margin improvement, PharmaCielo has not yet scaled enough to cover operating costs. Persistent EBIT and net losses weaken retained capital, reduce financial resilience, and make the durability of recent commercial improvement dependent on reaching break-even.

PharmaCielo News

PCLOF FAQ

What was PharmaCielo’s price range in the past 12 months?
PharmaCielo lowest stock price was $0.00 and its highest was $0.12 in the past 12 months.
What is PharmaCielo’s market cap?
PharmaCielo’s market cap is $6.56M.
When is PharmaCielo’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PharmaCielo’s earnings last quarter?
PharmaCielo released its earnings results on Jul 29, 2026. The company reported -$0.005 earnings per share for the quarter.
Is PharmaCielo overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does PharmaCielo pay dividends?
PharmaCielo does not currently pay dividends.
What is PharmaCielo’s EPS estimate?
PharmaCielo’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaCielo have?
PharmaCielo has 221,005,070 shares outstanding.
What happened to PharmaCielo’s price movement after its last earnings report?
PharmaCielo reported an EPS of -$0.005 in its last earnings report. Following the earnings report the stock price went down -9.524%.
Which hedge fund is a major shareholder of PharmaCielo?
Currently, no hedge funds are holding shares in PCLOF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology